Journal Mobile Options
Table of Contents
Vol. 53, No. 1, 2006
Issue release date: February 2006
Neuropsychobiology 2006;53:51–56

Association Analysis of the GSK-3β T–50C Gene Polymorphism with Schizophrenia and Bipolar Disorder

Szczepankiewicz A. · Skibinska M. · Hauser J. · Slopien A. · Leszczynska-Rodziewicz A. · Kapelski P. · Dmitrzak-Weglarz M. · Czerski P.M. · Rybakowski J.K.
aLaboratory of Psychiatric Genetics, Department of Psychiatry, bDepartment of Adult Psychiatry, and cDepartment of Child and Adolescent Psychiatry, Poznan University of Medical Sciences, Poznan, Poland

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Glycogen synthase kinase-3β (GSK-3β) has been implicated in the pathogenesis of major psychoses. In this paper, the T–50C polymorphism of the GSK-3β gene has been studied in patients with schizophrenia (n = 432), patients with bipolar disorder (n = 416) and in a healthy control group (n = 408). Consensus diagnosis by at least two psychiatrists was made for each patient, according to DSM-IV and ICD-10 criteria, using the Structured Clinical Interview for DSM-IV Axis I Disorders. Genotypes were established by the polymerase chain reaction-restriction fragment length polymorphism method. We have found a trend towards an association for the C allele in the whole group of schizophrenic patients (p = 0.088) and for the heterozygous T/C genotype of bipolar patients (0.095). Significant differences of genotype distribution and allele frequencies of the T–50C polymorphism were found in the female group of bipolar II patients (p = 0.015 for genotypes and p = 0.009 for alleles). In conclusion, this polymorphism may be associated with female gender in bipolar II disorder.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Arnold SE, Rioux L: Challenges, status, and opportunities for studying developmental neuropathology in adult schizophrenia. Schizophr Bull 2001;27:395–416.
  2. Cohen P: The role of protein phosphorylation in the hormonal control of enzyme activity. Eur J Biochem 1985;151:439–448.
  3. Leroy K, Brion JP: Developmental expression and localization of glycogen synthase kinase-3β in rat brain. J Chem Neuroanat 1999;16:279–293.
  4. Pei JJ, Braak E, Braak H, Grundke-Iqbal I, Iqbal K, Winblad B, Cowburn RF: Distribution of active glycogen synthase kinase 3β (GSK-3β) in brains staged for Alzheimer disease neurofibrillary changes. J Neuropathol Exp Neurol 1999;58:1010–1019.
  5. Woodgett JR: Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J 1990;9:2431–2438.
  6. Yu JS, Yang SD: Immunological and biochemical study on tissue and subcellular distributions of protein kinase FA (an activating factor of ATP-Mg-dependent protein phosphatase): a simplified and efficient procedure for high quantity purification from brain. J Protein Chem 1993;12:667–676.
  7. Woodgett JR: A common denominator linking glycogen metabolism, nuclear oncogenes and development. Trends Biochem Sci 1991;16:177–181.
  8. Shaw PC, Davies AF, Lau KF, Garcia-Barcelo M, Waye MM, Lovestone S, Miller CC, Anderton BH: Isolation and chromosomal mapping of human glycogen synthase kinase-3α and -3β encoding genes. Genome 1998;41:720–727.
  9. Srivastava AK, Pandey SK: Potential mechanism(s) involved in the regulation of glycogen synthesis by insulin. Mol Cell Biochem 1998;182:135–141.
  10. He X, Saint-Jeannet JP, Woodgett JR, Varmus HE and Dawid IB: Glycogen synthase kinase-3 and dorsoventral patterning in Xenopus embryos. Nature 1995;374:617–622.
  11. Kozlovsky N, Belmaker RH, Agam G: Low GSK-3β immunoreactivity in postmortem frontal cortex of schizophrenic patients. Am J Psychiatry 2000;157:831–833.
  12. Beasley C, Cotter D, Khan N, Pollard C, Sheppard P, Varndell I, Lovestone S, Anderton B, Everall I: Glycogen synthase kinase-3β immunoreactivity is reduced in the prefrontal cortex in schizophrenia. Neurosci Lett 2001;302:117–120.
  13. Kozlovsky N, Belmaker RH, Agam G: Low GSK-3 activity in frontal cortex of schizophrenic patients. Schizophr Res 2001;52:101–105.
  14. Agam G, Shaltiel G, Kozlovsky N, Shimon H, Belmaker RH: Lithium inhibitable enzymes in postmortem brain of bipolar patients. J Psychiatr Res 2003;37:433–442.
  15. Li X, Bijur GN, Jope RS: Glycogen synthase kinase-3β, mood stabilizers, and neuroprotection. Bipolar Disord 2002;4:137–144.
  16. O’Brien WT, Harper AD, Jove F, Woodgett JR, Maretto S, Piccolo S, Klein PS: Glycogen synthase kinase-3β haploinsufficiency mimics the behavioral and molecular effects of lithium. J Neurosci 2004;24:6791–6798.
  17. Gould TD, Chen G, Manji HK: In vivo evidence in the brain for lithium inhibition of glycogen synthase kinase-3. Neuropsychopharmacology 2004;29:32–38.
  18. Iwahana E, Akiyama M, Miyakawa K, Uchida A, Kasahara J, Fukunaga K, Hamada T, Shibata S: Effect of lithium on the circadian rhythms of locomotor activity and glycogen synthase kinase-3 protein expression in the mouse suprachiasmatic nuclei. Eur J Neurosci 2004;19:2281–2287.
  19. Gould TD, Zarate CA, Manji HK: Glycogen synthase kinase-3: a target for novel bipolar disorder treatments. J Clin Psychiatry 2004;65:10–21.
  20. Russ C, Lovestone S, Powell JF: Identification of sequence variants and analysis of the role of the glycogen synthase kinase 3β gene and promoter in late onset Alzheimer’s disease. Mol Psychiatry 2001;6:320–324.
  21. Lau KF, Miller CC, Anderton BH, Shaw PC: Molecular cloning and characterization of the human glycogen synthase kinase-3β promoter. Genomics 1999;60:121–128.
  22. Scassellati C, Bonvicini C, Perez J, Bocchio-Chiavetto L, Tura GB, Rossi G, Racagni G, Gennarelli M: Association study of –1727 A/T, –50 C/T and (CAA)n repeat GSK-3β gene polymorphisms with schizophrenia. Neuropsychobiology 2004;50:16–20.
  23. Benedetti F, Bernasconi A, Lorenzi C, Pontiggia A, Serretti A, Colombo C, Smeraldi E: A single nucleotide polymorphism in glycogen synthase kinase 3β promoter gene influences onset of illness in patients affected by bipolar disorder. Neurosci Lett 2004;355:37–40.
  24. First MB, Spitzer RL, Gibbon M, Williams J: Structured Clinical Interview for DSM-IV Axis I Disorders, Clinician Version (SCID-CV). Washington, American Psychiatric Press, 1996.
  25. Miller SA, Dykes DD, Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16:1215.
  26. Schulze TG, Muller DJ, Krauss H, Scherk H, Ohlraun S, Syagailo YV, Windemuth C, Neidt H, Grassle M, Papassotiropoulos A, Heun R, Nothen MM, Maier W, Lesch KP, Rietschel M: Association between a functional polymorphism in the monoamine oxidase A gene promoter and major depressive disorder. Am J Med Genet 2000;96:801–803.
  27. Liu W, Gu N, Feng G, Zhang J, Li S, Bai S, Shen T, Clair DS, He L: Association of VNTR region of the human serotonin transporter gene with bipolar disorder among the Han Chinese. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 1998;15:345–348.

    External Resources

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50